专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08697685B2 Chemical compounds 失效
标题翻译：化合物
公开(公告)号：US08697685B2
公开(公告)日：2014-04-15
申请号：US13130368
申请日：2009-11-18
申请人： Jeffrey Michael Axten , Charles William Blackledge, Jr. , Gerald Patrick Brady, Jr. , Yanhong Feng , Seth W. Grant , Jesus Raul Medina , William H. Miller , Stuart P. Romeril
发明人： Jeffrey Michael Axten , Charles William Blackledge, Jr. , Gerald Patrick Brady, Jr. , Yanhong Feng , Seth W. Grant , Jesus Raul Medina , William H. Miller , Stuart P. Romeril
IPC分类号： A61K31/33 , A61K31/54 , A61K31/505 , A61K31/55 , C07D401/08 , C07D417/02 , C07D413/06 , C07D239/02
CPC分类号： C07D403/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14
摘要： The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
摘要翻译：本发明涉及6-（4-嘧啶基）-1H-吲唑衍生物。具体地，本发明涉及式（I）的化合物，其中R 1 -R 4在本文中定义。本发明的化合物可以用于治疗由组成型激活的ACG激酶（例如癌症，更特别是乳腺癌，结肠癌和肺癌）特征的免疫和代谢疾病和病症的治疗。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还涉及抑制PDK1活性的方法和使用本发明化合物或与本发明化合物组合的药物组合物治疗与之相关的病症的方法。

2. 发明申请

US20110275611A1 CHEMICAL COMPOUNDS 失效
标题翻译：化学化合物
公开(公告)号：US20110275611A1
公开(公告)日：2011-11-10
申请号：US13130368
申请日：2009-11-18
申请人： Jeffrey Michael Axten , Charles William Blackledge, JR. , Gerald Patrick Brady, JR. , Yanhong Feng , Seth W. Grant , Jesus Raul Medina , William H. Miller , Stuart P. Romeril
发明人： Jeffrey Michael Axten , Charles William Blackledge, JR. , Gerald Patrick Brady, JR. , Yanhong Feng , Seth W. Grant , Jesus Raul Medina , William H. Miller , Stuart P. Romeril
IPC分类号： A61K31/506 , C07D417/14 , C07D413/14 , C07D401/14 , A61K31/541 , A61K31/5377 , C07D403/14 , A61K31/55 , C07D471/04 , A61P35/00 , A61P35/02 , A61P3/10 , A61P37/06 , A61P17/06 , A61P1/00 , C07D403/10
CPC分类号： C07D403/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14
摘要： The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention
摘要翻译：本发明涉及6-（4-嘧啶基）-1H-吲唑衍生物。具体地，本发明涉及式（I）的化合物，其中R 1 -R 4在本文中定义。本发明的化合物可以用于治疗由组成型激活的ACG激酶（例如癌症，更特别是乳腺癌，结肠癌和肺癌）特征的免疫和代谢疾病和病症的治疗。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物抑制PDK1活性和与之相关疾病的治疗方法

3. 发明授权

US08536179B2 Indoles 有权
标题翻译：吲哚
公开(公告)号：US08536179B2
公开(公告)日：2013-09-17
申请号：US13696362
申请日：2011-05-05
申请人： William H. Miller , Xinrong Tian , Sharad Kumar Verma
发明人： William H. Miller , Xinrong Tian , Sharad Kumar Verma
IPC分类号： A61K31/497
CPC分类号： A61K31/496 , A61K31/405 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D498/04
摘要： Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful in treating cancer.
摘要翻译：本文公开了式（I）的吲哚，其中各种基团在本文中定义，并且其可用于治疗癌症。

4. 发明授权

US07524843B2 Fab I inhibitors 失效
标题翻译： Fab I抑制剂
公开(公告)号：US07524843B2
公开(公告)日：2009-04-28
申请号：US11779578
申请日：2007-07-18
申请人： William H. Miller , Kenneth A. Newlander , Mark A. Seefeld , Irene N. Uzinskas , Walter E. Dewolf, Jr. , Dalia R. Jakas
发明人： William H. Miller , Kenneth A. Newlander , Mark A. Seefeld , Irene N. Uzinskas , Walter E. Dewolf, Jr. , Dalia R. Jakas
IPC分类号： A61K31/4375 , C07D265/36
CPC分类号： C07D213/75 , A61K31/381 , A61K31/4436 , A61K31/4439 , A61K31/47 , A61K31/495 , A61K31/506 , A61K31/5365 , C07D209/14 , C07D209/52 , C07D239/42 , C07D401/12 , C07D405/12 , C07D471/04 , C07D487/04 , C07D495/04 , Y02A50/473
摘要： Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.
摘要翻译：公开了式（I）的化合物，其是Fab I抑制剂并且可用于治疗细菌感染。

5. 发明授权

US06730684B1 Fab I inhibitors 失效
标题翻译： Fab I抑制剂
公开(公告)号：US06730684B1
公开(公告)日：2004-05-04
申请号：US10089740
申请日：2002-04-03
申请人： William H. Miller , Kenneth A. Newlander , Mark A. Seefeld , Irene N. Uzinskas
发明人： William H. Miller , Kenneth A. Newlander , Mark A. Seefeld , Irene N. Uzinskas
IPC分类号： A61K31445
CPC分类号： C07D401/12 , C07D209/14 , C07D231/56
摘要： Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infections.
摘要翻译：公开了式（I）和（II）的化合物，其中R 1，R 2，R 3，R 4，X，A，B，D和Q如说明书中所公开的，该化合物是可用于治疗细菌感染的FabI抑制剂。

6. 发明授权

US06495560B1 Vitronectin receptor antagonist 有权
标题翻译： Vitronectin受体拮抗剂
公开(公告)号：US06495560B1
公开(公告)日：2002-12-17
申请号：US09857316
申请日：2001-07-12
申请人： William H. Miller , Peter J. Manley
发明人： William H. Miller , Peter J. Manley
IPC分类号： A61K31435
CPC分类号： C07D471/04 , A61K31/47 , A61K33/24 , A61K31/435 , A61K2300/00
摘要： A compound of the formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis: or a pharmaceutically acceptable salt thereof.
摘要翻译：公开了式（I）化合物，其是玻连蛋白受体拮抗剂，可用于治疗骨质疏松症：或其药学上可接受的盐。

7. 发明授权

US6159964A Vitronectin receptor antagonists 失效
标题翻译： Vitronectin受体拮抗剂
公开(公告)号：US6159964A
公开(公告)日：2000-12-12
申请号：US91937
申请日：1999-07-27
申请人： Fadia E. Ali , William E. Bondinell , Richard M. Keenan , Thomas Wen-Fu Ku , William H. Miller , James Samanen
发明人： Fadia E. Ali , William E. Bondinell , Richard M. Keenan , Thomas Wen-Fu Ku , William H. Miller , James Samanen
IPC分类号： A61K31/00 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4545 , A61K31/47 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/4965 , A61K31/497 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/5517 , A61P7/02 , A61P9/00 , A61P9/10 , A61P19/00 , A61P19/08 , A61P29/00 , A61P35/00 , A61P43/00 , C07D213/73 , C07D213/74 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D487/04
CPC分类号： C07D213/74 , C07D401/12 , C07D403/12 , C07D405/12 , C07D487/04
摘要： Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form --(CHR.sup.g).sub.a --U--(CHR.sup.g).sub.b --V--; Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 are independently N or C--R.sup.y, provided that no more than one Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 is N; R' is H or C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 -alkyl or Ar--C.sub.0-6 alkyl; R.sup.g is H or C.sub.1-6 alkyl, Het-C.sub.0-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl or Ar--C.sub.0-6 alkyl; R.sup.k is R.sup.g, --C(O)R.sup.g or --C(O)OR.sup.g R.sup.i is H, C.sub.1-6 alkyl, Het-C.sub.0-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl, Ar--C.sub.0-6 alkyl, Het-C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl or Ar--C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl; R.sup.y is H, halo, --OR.sup.g, --SR.sup.g, --CN, --NR.sup.g R.sup.k, --NO.sub.2, --CF.sub.3, CF.sub.3 S(O).sub.r, --CO.sub.2 R.sup.g, --COR.sup.g or --CONR.sup.g.sub.2, or C.sub.1-6 alkyl optionally substituted by halo, --OR.sup.g, --SR.sup.g, --CN, --NR.sup.8 R", --NO.sub.2, --CF.sub.3, R'S(O).sub.3 --, --CO.sub.2 R.sup.g, --COR.sup.g or --CONR.sup.g.sub.2 ; U and V are absent or CO, CR.sup.g.sub.2, C(.dbd.CR.sup.g.sub.2), S(O).sub.c, O, NR.sup.g, CR.sup.g OR.sup.g, CR.sup.g (OR.sup.k)CR.sup.g.sub.2, CR.sup.g.sub.7 CR.sup.g (OR.sup.k), C(O)CR.sup.g.sub.2, CR.sup.g.sub.2 C(O), CONR.sup.i, NR.sup.i CO, OC(O), C(O)O, OC(S), C(S)NR.sup.g, NR.sup.8 C(S), S(O.sub..sub.2 NR.sup.g, NR.sup.g S(O).sub.2 N.dbd.N, NR.sup.g NR.sup.g, NR.sup.g CR.sup.g.sub.2, NR.sup.g CR.sup.g.sub.2, CR.sup.g.sub.2 O, OCR.sup.g.sub.2, CR.sup.g .dbd.CR.sup.g, C.ident.C, Ar or Het; a is 0, 1 or 2; c is 0, 1 or 2; r is 0, 1 or 2; and u is 0 or 1; or pharmaceutically acceptable salts thereof, which are vitronectin receptor antagonists useful in the treatment of osteoporosis. ##STR1##
摘要翻译： PCT No.PCT / US96 / 20327 Sec。 371日期：1999年7月27日 102（e）日期1999年7月27日PCT 1996年12月20日PCT PCT。公开号WO97 / 24124 日期1999年7月10日公开了式（I）的化合物，其中：A是纤维蛋白原拮抗剂模板; W是 - （CHRg）a-U-（CHRg）b-V-的形式的连接部分; Q1，Q2，Q3和Q4独立为N或C-Ry，条件是不超过一个Q1，Q2，Q3和Q4为N; R'是H或C 1-6烷基，C 3-7环烷基-C 0-6 - 烷基或Ar-C 0-6烷基; R g是H或C 1-6烷基，Het-C 0-6烷基，C 3-7环烷基-C 0-6烷基或Ar-C 0-6烷基; R k是R g，-C（O）R g或-C（O）OR g R 1是H，C 1-6烷基，Het-C 0-6烷基，C 3-7环烷基-C 0-6烷基，Ar-C 0-6烷基，Het-C 0-6烷基 -N''-C 1-6烷基，C 3-7环烷基-C 0-6烷基-U'-C 1-6烷基或Ar-C 0-6烷基-U'-C 1-6烷基; R y是H，卤素，-OR g，-SR g，-CN，-NR g R k，-NO 2，-CF 3，CF 3 S（O）r，-CO 2 R g，-COR g或-CONRg 2，或任选被卤素取代的C 1-6烷基，-OR g ，-SRg，-CN，-NR 8 R“，-NO 2，-CF 3，R'（O）3 - ，-CO 2 R g，-COR g或-CONRg 2; U和V不存在或CO，CRg2，C（= CRg2），S（O）c，O，NRg，CRgORg，CRg（ORk）CRg2，CRg7CRg（ORk），C（O）CRg2，CRg2C（O） C（O）O，OC（S），C（S）NR g，NR 8 C（S），S（O 2 NRR，NR g S（O）2 N = N，NR g NRR，NR g CR 2，NR g CR 2，，OCRg2，CRg = CRg，C = C，Ar或Het; a为0,1或2; c为0,1或2; r为0,1或2; u为0或1;或药学上可接受的盐它们是可用于治疗骨质疏松症的玻连蛋白受体拮抗剂。

8. 发明授权

US5347129A System for determining the type of nuclear radiation from detector output pulse shape 失效
标题翻译：用于从检测器输出脉冲形状确定核辐射类型的系统
公开(公告)号：US5347129A
公开(公告)日：1994-09-13
申请号：US48272
申请日：1993-04-14
申请人： William H. Miller , Ronald R. Berliner
发明人： William H. Miller , Ronald R. Berliner
IPC分类号： G01T1/17 , G01T1/00 , G01T1/15
CPC分类号： G01T1/17
摘要： A radiation detection system determines the type of nuclear radiation received in a detector by producing a correlation value representative of the statistical cross correlation between the shape of the detector signal and pulse shape data previously stored in memory and characteristic of respective types of radiation. The correlation value is indicative of the type of radiation. The energy of the radiation is determined from the detector signal and is used to produce a spectrum of radiation energies according to radiation type for indicating the nature of the material producing the radiation.
摘要翻译：辐射检测系统通过产生表示检测器信号的形状和先前存储在存储器中的脉冲形状数据与各种类型的辐射的特性之间的统计互相关的相关值来确定在检测器中接收的核辐射的类型。相关值表示辐射的类型。辐射的能量由检测器信号确定，并用于产生根据辐射类型的辐射能量谱，以指示产生辐射的材料的性质。

9. 发明授权

US5134766A Automatic weight application machine 失效
标题翻译：自动重量应用机
公开(公告)号：US5134766A
公开(公告)日：1992-08-04
申请号：US681885
申请日：1991-04-08
申请人： William H. Miller
发明人： William H. Miller
IPC分类号： F16F15/32 , G01M1/32
CPC分类号： G01M1/326 , F16F15/32 , Y10T29/4987 , Y10T29/49876 , Y10T29/49945 , Y10T29/53391 , Y10T29/53657 , Y10T29/53783 , Y10T29/53991 , Y10T29/53996
摘要： A machine for automatically applying a balance correcting weight (44)-and-clip (46) assembly to vehicle wheel-and-tire assembly (12). The machine includes a conveyor (20) portion for conveying the wheel-and-tire assembly (12) to a weight (44) application station, orienting the wheel-and-tire assembly (12) properly to receive at the correct location the balance-correcting weight (44), and conveying the wheel-and-tire assembly (12) to which the balance-correcting weight (44) has been applied away from the weight (44) application station. The machine includes a hammer (22, 24) having a storage orientation out of operating position permitting conveying of the wheel-and-tire assembly (12) to and from the weight (44) application station and a use orientation in operating position adjacent the wheel-and-tire assembly (12) to which balance correcting weight (44) is to be applied, and means for moving the hammer (22, 24) selectively between its storage and use orientations. The hammer (22, 24) includes a jaw (40) with a contour conforming to the shape of the clip (46) and a shank (50) portion of ferromagnetic material, said shank (50) being surrounded by an electrically conductive coil (94).
摘要翻译：一种用于自动将平衡校正重物（44）和夹子（46）组件应用于车轮和轮胎组件（12）的机器。机器包括用于将轮胎和轮胎组件（12）输送到重物（44）施加工位的输送机（20）部分，适当地使轮胎和轮胎组件（12）定向以在正确位置处接收平衡 - 修正重量（44），并且将已经施加有平衡校正重块（44）的轮胎和轮胎组件（12）输送到配重（44）施加站。该机器包括具有不在操作位置的存储方向的锤子（22,24），允许轮胎和轮胎组件（12）运送到重物（44）施加工位和从重物（44）施加工位移动，并且在与要施加平衡矫正重量（44）的轮胎和轮胎组件（12），以及用于在其存储和使用取向之间选择性地移动锤（22,24）的装置。锤子（22,24）包括具有与夹子（46）的形状相符的轮廓和铁磁材料的柄（50）部分的钳口（40），所述杆（50）被导电线圈 94）。

10. 发明授权

US5048173A Automatic weight application machine 失效
公开(公告)号：US5048173A
公开(公告)日：1991-09-17
申请号：US435483
申请日：1989-04-24
申请人： William H. Miller
发明人： William H. Miller
IPC分类号： F16F15/32 , G01M1/32
CPC分类号： F16F15/32 , G01M1/326 , Y10T29/4987 , Y10T29/49876 , Y10T29/49945 , Y10T29/53391 , Y10T29/53657 , Y10T29/53783 , Y10T29/53991 , Y10T29/53996
摘要： A machine is provided for automatically applying a balance correcting weight (44)-and-clip (46) assembly to a vehicle wheel-and-tire assembly (12). The machine includes a conveyor (20) portion for conveying the wheel-and-tire assembly (12) to which the balance-correcting weight (44) is to be applied to a weight (44) application station, orienting the wheel-and-tire assembly (12) properly to receive at the correct location the balance-correcting weight (44), and conveying the wheel-and-tire assembly (12) to which the balance-correcting weight (44) has been applied away from the weight (44) application station. The machine includes a hammer (22, 24) having a storage orientation permitting conveying of the wheel-and-tire assembly (12) to and from the weight (44) application station and a use orientation adjacent the wheel-and-tire assembly (12) to which balance correcting weight (44) is to be applied, and means for moving the hammer (22, 24) selectively between its storage and use orientations to permit conveying of the wheel-and-tire assembly (12) to the weight (44) application station, application of the balance-correcting weight (44) to the wheel-and-tire assembly (12), and conveying of the wheel-and-tire assembly (12) to which a balance correcting weight (44) has been attached away from the weight (44) application station. The hammer (22, 24) includes a jaw (40) with a contour conforming to the shape of the clip (46) and a shank (50) portion. The shank (50) portion and jaw (40) comprise ferromagnetic material. An electrically conductive coil (94) surrounds the shank (50) portion of the hammer (22, 24). The hammer (22, 24) is driven through operating cycles to hammer (22, 24) the weight (44)-and-clip (46) assembly onto the wheel.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式